Receptor, Cannabinoid, CB2
"Receptor, Cannabinoid, CB2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of cannabinoid receptor found primarily on immune cells where it may play a role modulating release of CYTOKINES.
Descriptor ID |
D043885
|
MeSH Number(s) |
D12.776.543.750.695.125.200
|
Concept/Terms |
Receptor, Cannabinoid, CB2- Receptor, Cannabinoid, CB2
- CB2 Receptor
- Receptor, CB2
- Cannabinoid Receptor CB2
- CB2, Cannabinoid Receptor
- Receptor CB2, Cannabinoid
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Cannabinoid, CB2".
Below are MeSH descriptors whose meaning is more specific than "Receptor, Cannabinoid, CB2".
This graph shows the total number of publications written about "Receptor, Cannabinoid, CB2" by people in this website by year, and whether "Receptor, Cannabinoid, CB2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 1 | 0 | 1 |
2010 | 1 | 0 | 1 |
2011 | 2 | 0 | 2 |
2014 | 2 | 0 | 2 |
2015 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Cannabinoid, CB2" by people in Profiles.
-
Myers AM, Siegele PB, Foss JD, Tuma RF, Ward SJ. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Br J Pharmacol. 2019 05; 176(10):1552-1567.
-
Ward SJ, Castelli F, Reichenbach ZW, Tuma RF. Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci. 2018 Feb 15; 195:1-5.
-
Ronca RD, Myers AM, Ganea D, Tuma RF, Walker EA, Ward SJ. A selective cannabinoid CB2 agonist attenuates damage and improves memory retention following stroke in mice. Life Sci. 2015 Oct 01; 138:72-7.
-
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014 Nov 01; 144:12-41.
-
Mohr AL, Ofsa B, Keil AM, Simon JR, McMullin M, Logan BK. Enzyme-linked immunosorbent assay (ELISA) for the detection of use of the synthetic cannabinoid agonists UR-144 and XLR-11 in human urine. J Anal Toxicol. 2014 Sep; 38(7):427-31.
-
Adhikary S, Li H, Heller J, Skarica M, Zhang M, Ganea D, Tuma RF. Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. J Neurotrauma. 2011 Dec; 28(12):2417-27.
-
Elliott MB, Tuma RF, Amenta PS, Barbe MF, Jallo JI. Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. J Neurotrauma. 2011 Jun; 28(6):973-81.
-
Carvalho AF, Reyes AR, Sterling RC, Unterwald E, Van Bockstaele EJ. Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology (Berl). 2010 Sep; 211(4):479-91.
-
Heller JE, Baty DE, Zhang M, Li H, Adler M, Ganea D, Gaughan J, Loftus CM, Jallo JI, Tuma RF. The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury. Clin Neurosurg. 2009; 56:84-92.